@article{ATM26470,
author = {Vincenzo Di Nunno and Francesco Massari and Veronica Mollica and Alessia Cimadamore and Matteo Santoni and Liang Cheng and Antonio Lopez-Beltran and Marina Scarpelli and Rodolfo Montironi},
title = {Another one in the chamber: cabozantinib for patients with metastatic non clear cell renal cell carcinoma},
journal = {Annals of Translational Medicine},
volume = {7},
number = {Suppl 3},
year = {2019},
keywords = {},
abstract = {The term ‘’Non-clear cell Renal Cell Carcinoma (nccRCC)’’ recognized a large series of renal tumours characterized of a specific genomic and morphological signature. Compared to clear cell renal cell carcinoma (ccRCC), these tumours are uncommon diagnoses with an overall incidence around 20–25% of primary kidney tumours) (1).},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/26470}
}